Axsome Therapeutics, Inc. AXSM
149.24 USD +8.27 (+5.87%)
Nov 11, 2026, 3:59 PM EST
141.41 Day range 151.31
123.00 52-week range 260.19
- YTD
- -18.29%
- 1 year
- +6.90%
News
marketbeat.com Axsome Therapeutics Tops $1 Billion Revenue Run Rate as AUVELITY Sales Surge Axsome Therapeutics NASDAQ: AXSM reported $260 million in third-quarter revenue, driven by growth in its AUVELITY treatment for major depressive disorder and Alzheimer's disease agitation, executives…
seekingalpha.com Axsome Therapeutics, Inc. (AXSM) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript Axsome Therapeutics, Inc. ( AXSM ) 3rd Annual Guggenheim Healthcare Innovation Conference November 9, 2026 11:30 AM EST Company Participants Mark Jacobson - Chief Operating Officer Nick Pizzie -…
fool.com Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027? Axsome Therapeutics is generating rapid revenue growth from its expanding portfolio of central nervous system treatments. BioNTech maintains a massive cash position and virtually no debt while…
fool.com Axsome: 3 Key Takeaways for Long-Term Investors Third-quarter revenue grew 52% year over year to $260 million. Management expects Auvelity to reach $8 billion in peak annual revenue.
benzinga.com Mizuho Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $272 Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $284 to $272.
benzinga.com Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $249 Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and raises the price target from $247 to $249.
benzinga.com UBS Maintains Buy on Axsome Therapeutics, Lowers Price Target to $239 UBS analyst Ashwani Verma maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $256 to $239.
benzinga.com RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $273 RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $295 to $273.
benzinga.com Guggenheim Maintains Buy on Axsome Therapeutics, Lowers Price Target to $250 Guggenheim analyst Yatin Suneja maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $275 to $250.- benzinga.com Baird Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $220 Baird analyst Joel Beatty maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $246 to $220.
benzinga.com Dow Rises 1%, Oil Sinks 7% on Iran Peace Hopes: Stock Market Today Oil tumbles on renewed U.S.-Iran diplomacy, pulling Treasury yields lower and lifting the Dow, airlines and Amazon while energy stocks lag.
benzinga.com Axsome Therapeutics Q3 2026 Earnings Call Transcript Axsome Therapeutics (NASDAQ:AXSM) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Axsome Therapeutics Q3 EPS $(0.25) Beats $(0.56) Estimate, Sales $259.691M Beat $249.929M Estimate Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.56) by 55.36 percent. This is a 73.4 percent increase over losses of…
benzinga.com Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test Apple headlines Monday’s reports, with investors looking for continued iPhone momentum and evidence that its artificial-intelligence push can support the company’s next leg of growth. Marriott…
benzinga.com Piper Sandler Maintains Overweight on Axsome Therapeutics, Lowers Price Target to $238 Piper Sandler analyst David Amsellem maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and lowers the price target from $258 to $238.
benzinga.com Top 3 Health Care Stocks That Could Blast Off In October Insmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.
benzinga.com RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $295 RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $297 to $295.
benzinga.com Deutsche Bank Maintains Buy on Axsome Therapeutics, Lowers Price Target to $267 Deutsche Bank analyst David Hoang maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $280 to $267.
benzinga.com Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
benzinga.com Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $247 Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and lowers the price target from $251 to $247.
benzinga.com $100 Invested In Axsome Therapeutics 10 Years Ago Would Be Worth This Much Today Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 10 years by 24.39% on an annualized basis producing an average annual return of 37.87%. Currently, Axsome Therapeutics has…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Truist Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $285 Truist Securities analyst Srikripa Devarakonda maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $200 to $285.
- benzinga.com Axsome Therapeutics Highlights Alzheimer’s Agitation Impact In Shared Goals Survey The Shared Goals: Navigating Alzheimer’s Agitation survey finds that Alzheimer’s disease agitation is often only recognized after daily life is significantly disruptedNinety-seven percent of care…
benzinga.com 5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In U.S. stocks ended mixed; the Dow had its worst week since March. Benzinga highlights top picks from five accurate analysts, including ON, AXSM and LLY.- benzinga.com Piper Sandler Reiterates Overweight on Axsome Therapeutics, Maintains $258 Price Target Piper Sandler analyst David Amsellem reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $258 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $290 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Buy and maintains $290 price target.
- benzinga.com Axsome Therapeutics Dosed First Patient in SUMMIT Phase 3 Trial of AXS-05 For Smoking Cessation Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been…
benzinga.com Target To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday Wall Street analysts changed outlook on top names. See complete view of all changes, upgrades, downgrades on analyst ratings page.
benzinga.com This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, with positive outlooks and raised price targets.
benzinga.com This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.benzinga.com/analyst-stock-ratings. INSM initiated with $192 PT.- benzinga.com 9 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com 10 Health Care Stocks Whale Activity In Today's Session - benzinga.com 'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants' - Reuters Exclusive Health officials explored restricting specific antidepressants among SSRI drugs-sources
benzinga.com Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big Stocks Moving Higher On Monday Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday after reporting better-than-expected financial results. Other top gainers included companies like…
benzinga.com Earnings Scheduled For May 4, 2026 
benzinga.com Axsome Wins FDA Nod For Expanded Use For Auvelity Beyond Depression FDA clears Axsome's Auvelity for Alzheimer's agitation, backed by Phase 3 data, expanding its use beyond depression in a large market.
benzinga.com Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipeline amid bullish analyst targets.- benzinga.com Axsome Therapeutics Enters Into An Asset Purchase Agreement To Obtain Exclusive Global Rights To TAK-063 (balipodect) From Takeda, Deal Terms Undisclosed Under the terms of the agreement, Axsome obtained worldwide commercial, development, and manufacturing rights to balipodect. Takeda received an upfront payment and is eligible to receive additional…
benzinga.com This Gentherm Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - benzinga.com PPL Plans To Sell 20M Equity Units In Public Offering PPL Corporation (NYSE:PPL) announced it plans to sell 20,000,000 equity units in a public offering. Each equity unit will be issued in a stated amount of $50 ($1,000,000,000 aggregate stated amount)…
- benzinga.com Earnings Scheduled For February 23, 2026
benzinga.com Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment William Blair upgrades Neumora after strong Alzheimer's agitation data, sees upside from NMRA-511 and obesity pipeline potential.
benzinga.com Why FuelCell Energy Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Axsome Therapeutics, Plug Power And Other Big Stocks Moving Higher On Wednesday 
benzinga.com Earnings Scheduled For November 3, 2025 
benzinga.com Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years FDA approves Tonmya, a non-opioid fibromyalgia therapy from Tonix, with strong trial data and U.S. launch expected in late 2025.- benzinga.com Earnings Scheduled For August 4, 2025
- benzinga.com Earnings Scheduled For May 5, 2025